Taiyen Biotech Co

Taiyen Biotech Co Current Assets

The Current Assets of Taiyen Biotech Co (1737.TW) as of Oct 27, 2026 is 2.22 B TWD. In the previous year, Current Assets was 2.93 B TWD — a change of -24.08% (lower).

Current Assets

2.22 BTWD

YoY

-24.08%

Last updated:

Current Assets of Taiyen Biotech Co is 2025 2.22 B TWD. Current Assets of Taiyen Biotech Co was 2024 2.93 B TWD. It decreases by -24.08% lower compared to the previous year.

The Taiyen Biotech Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
2.77 B TWD
Jan 1, 2019
2.70 B TWD
Jan 1, 2020
2.87 B TWD
Jan 1, 2021
3.39 B TWD
Jan 1, 2022
3.06 B TWD
Jan 1, 2023
3.00 B TWD
Jan 1, 2024
2.93 B TWD
Jan 1, 2025
2.22 B TWD
The Taiyen Biotech Co Current Assets history
YEARCurrent AssetsYoY
2.22 BTWD-24.08%
2.93 BTWD-2.51%
3.00 BTWD-1.91%
3.06 BTWD-9.82%
3.39 BTWD+18.43%
2.87 BTWD+6.23%
2.70 BTWD-2.66%
2.77 BTWD+2.47%
2.71 BTWD-0.47%
2.72 BTWD+16.42%
2.33 BTWD+8.50%
2.15 BTWD+8.62%
1.98 BTWD-24.10%
2.61 BTWD-13.19%
3.01 BTWD+3.65%
2.90 BTWD-0.41%
2.91 BTWD+480.54%
501.73 MTWD-49.92%
1.00 BTWD-65.09%
2.87 BTWD+183.77%
1.01 BTWD-13.66%
1.17 BTWD-16.11%
1.40 BTWD-87.69%
11.35 BTWD+48.42%
7.64 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Taiyen Biotech Co Stock analysis

What does Taiyen Biotech Co do? Taiyen Biotech Co Ltd is a Taiwanese company specializing in the development of food ingredients and biologically active substances. It was founded in 2002 by Dr. Yau-Lin Tseng, a renowned food chemist. Since its founding, Taiyen Biotech has developed and launched a wide range of products and services. The company focuses on the production of dietary supplements and functional foods that are intended to improve health and well-being. The business strategy of Taiyen Biotech is to produce innovative and scientifically supported products that meet the needs of customers. The company relies on intensive research and development to constantly improve its products and explore new markets. It collaborates closely with other industry, science, and technology partners. One of the most well-known divisions of Taiyen Biotech is the production of fermented dietary supplements based on microorganisms. The company has developed a series of innovative products that contain high concentrations of live bacterial cultures and are targeted towards various health needs and issues. Some of Taiyen Biotech's most famous products include food additives like Lactobacillus acidophilus-Lafti®L10, probiotic bacteria that support the immune system and inhibit the growth of pathogenic bacteria. Another product is Hydroxytyrosol, an antioxidant derivative of acetic acid that is used to combat oxidative stress and prevent chronic diseases such as cancer and cardiovascular diseases. Taiyen Biotech also offers services in the field of biotechnology, including the development of fermentation processes, the production of plant and animal cell cultures, and the manufacturing of enzymes and bioactive compounds. The products of Taiyen Biotech are distributed in many countries worldwide, including the USA, Europe, Asia, and Australia. The company is ISO 22000 certified and has received international certificates and recognition for its products and services. Overall, Taiyen Biotech has experienced high growth in recent years and has become a significant player in the global market for food ingredients and biologically active compounds. The company aims to further strengthen its market presence in the coming years and develop innovative products that meet the needs of customers. Taiyen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Taiyen Biotech Co stock

Current Assets of Taiyen Biotech Co is 2.22 B TWD in 2025.

Current Assets of Taiyen Biotech Co changed from 2.93 B TWD to 2.22 B TWD, representing a -24.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Taiyen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Taiyen Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Taiyen Biotech Co

All Key Metrics — Taiyen Biotech Co